Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, which speaks to the promise of the FDA-approved garadacimab.
Timothy Craig, DO
Advertisement
Articles by Timothy Craig, DO
The recent approval of garadacimab can help to treat patients with hereditary angioedema (HAE) along with sebetralstat, which is awaiting FDA approval, explains Timothy Craig, DO, Penn State Health.
With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
2
New Insight on Biologic Initiation Patterns for Treating Severe Asthma
3
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
4
Predicting Patient Response in the Move Toward Precision Medicine in Myasthenia Gravis
5
